Impact of routine follow-up examinations on life expectancy in ovarian cancer patients: A simulation study

International Journal of Gynecological Cancer

Volumn 22, Issue 7, 2012, Pages 1150-1157

  Geurts, Sandra M E ^a   De Vegt, Femmie ^a   Van Altena, Anne M ^a   Tjan Heijnen, Vivianne C G ^b   Massuger, Leon F A G ^a   Adang, Eddy M ^a   Van Dijck, Jos A A M ^a   Verbeek, André L M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Life expectancy; Markov model; Ovarian cancer; Routine follow up

Indexed keywords

ADULT; AGED; CANCER MORTALITY; CANCER PATIENT; CANCER REGRESSION; CONFERENCE PAPER; DISEASE COURSE; DISEASE SEVERITY; FEMALE; FOLLOW UP; HUMAN; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; RECURRENCE RISK; SIMULATION; SURVIVAL RATE; ADENOCARCINOMA; ARTICLE; CANCER STAGING; COLLOID CARCINOMA; COMPUTER SIMULATION; CYSTADENOCARCINOMA; ENDOMETRIUM TUMOR; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; OVARY TUMOR; PATHOLOGY; PROBABILITY; PROGNOSIS; QUALITY ADJUSTED LIFE YEAR; RETROSPECTIVE STUDY; TUMOR RECURRENCE;

ADENOCARCINOMA; ADENOCARCINOMA, MUCINOUS; ADULT; AGED; AGED, 80 AND OVER; COMBINED MODALITY THERAPY; COMPUTER SIMULATION; CYSTADENOCARCINOMA, SEROUS; ENDOMETRIAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIFE EXPECTANCY; MARKOV CHAINS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OVARIAN NEOPLASMS; PROGNOSIS; QUALITY-ADJUSTED LIFE YEARS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84873272537     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e3182611451     Document Type: Conference Paper

References (27)

1. Massuger LF, Kruitwagen RFPM, Coppens JMB, et al. Epithelial Ovarian Carcinoma. National Guideline [in Dutch]. CRGO; 2009. Available at: www.oncoline.nl. Accessed February 21, 2011.
2. Health Council of the Netherlands. Follow-up in Oncology. Identify Objectives, Substantiate Actions. Report No. 2007/10. The Hague, The Netherlands: Health Council of the Netherlands; 2007.
3. Colombo N, Peiretti M, Parma G, et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21:v23-v30.
4. Rustin GJ, van der Burg MEL, Griffin CL, et al. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet. 2010;376:1155-1163.
5. Geurts SME, de Vegt F, van Altena AM, et al. Considering early detection of relapsed ovarian cancer: a review of the literature. Int J Gynecol Cancer. 2011;21:837-845.
6. Ritoe SC, de Vegt F, Scheike IM, et al. Effect of routine follow-up after treatment for laryngeal cancer on life expectancy and mortality: results of a Markov model analysis. Cancer. 2007;109:239-247.
7. Jacobs HJM, van Dijck JAAM, de Kleijn EMHA, et al. Routine follow-up examinations in breast cancer patients have minimal impact on life expectancy: a simulation study. Ann Oncol. 2001;12:1107-1113.
8. Geurts SME, van Altena AM, de Vegt F, et al. No supportive evidence for clinical benefit of routine follow-up in ovarian cancer: a Dutch multicenter study. Int J Gynecol Cancer. 2011;21:647-653.
9. Hunink MG, Glasziou PP, Siegel JE, et al. Decision Making in Health and Medicine. Cambridge: Cambridge University Press; 2001.
10. Fung-Kee-Fung M, Oliver T, Elit L, et al. Optimal chemotherapy treatment for women with recurrent ovarian cancer. Curr Oncol. 2007;14:195-208.
11. Beck JR, Kassirer JP, Pauker SG. A convenient approximation of life expectancy (the "DEALE"). I. Validation of the method. Am J Med. 1982;73:883-888.
12. Statistics Netherlands. Statline Database 2009: Life Table. Available at: www.cbs.nl. Accessed November 30, 2010.
13. van Altena AM, Kolwijck E, Spanjer MJB, et al. CA125 nadir concentration is an independent predictor of tumor recurrence in patients with ovarian cancer: a population-based study. Gynecol Oncol. 2010;119:265-269.
14. Gadducci A, Fuso L, Cosio S, et al. Are surveillance procedures of clinical benefit for patients treated for ovarian cancer?: a retrospective Italian multicentric study. Int J Gynecol Cancer. 2009;19:367-374.
15. Ovarian Cancer National Alliance (www.ovariancancer.org)
16. and SEER Cancer Statistics Review. StatBite: ovarian cancer: risk of recurrence by stage of diagnosis. J Natl Cancer Inst. 2009;101:1234.
17. Tanner EJ, Chi DS, Eisenhauer EL, et al. Surveillance for the detection of recurrent ovarian cancer: survival impact or lead-time bias? Gynecol Oncol. 2010;117:336-340.
18. Hopkins ML, Coyle D, Le T, et al. Cancer antigen 125 in ovarian cancer surveillance: a decision analysis model. Curr Oncol. 2007;14:167-172.
19. Sivanesaratnam V. Third S.S. Ratnam Memorial Lecture 2007. Ovarian cancer: is there hope for women? J Obstet Gynaecol Res. 2009;35:393-404.
20. Fitch MI, Steele R. Identifying supportive care needs of women with ovarian cancer. Can Oncol Nurs J. 2010;20:66-74.
21. Cox A, Bull E, Cockle-Hearne J, et al. Nurse led telephone follow up in ovarian cancer: a psychosocial perspective. Eur J Oncol Nurs. 2008;12:412-417.
22. Steele R, Fitch MI. Supportive care needs of women with gynecologic cancer. Cancer Nurs. 2008;31:284-291.
23. Rettenmaier NB, Rettenmaier CR, Wojciechowski T, et al. The utility and cost of routine follow-up procedures in the surveillance of ovarian and primary peritoneal carcinoma: a 16-year institutional review. Br J Cancer. 2010;103:1657-1662.
24. Lewis R, Neal RD, Williams NH, et al. Nurse-led vs. conventional physician-led follow-up for patients with cancer: systematic review. J Adv Nurs. 2009;65:706-723.
25. Brown L, Payne S, Royle G. Patient initiated follow up of breast cancer. Psychooncology. 2002;11:346-355.
26. Van der Zee AGJ, Colombo N, Gitsch G, et al. ESGO statement on the role of CA-125 measurement in follow-up of epithelial ovarian cancer. Int J Gynecol Cancer. 2012;22:175.
27. Verheijen RHM, Cibula D, Zola P, Reed N. Cancer antigen 125: lost to follow-up?: A European Society of Gynaecological Oncology Consensus Statement. Int J Gynecol Cancer. 2012;22:170-174.